| Combining the strengths of radiologists and AI for breast cancer screening: a retrospective analysis C Leibig, M Brehmer, S Bunk, D Byng, K Pinker, L Umutlu The Lancet Digital Health 4 (7), e507-e519, 2022 | 110 | 2022 |
| Does pharmaceutical pricing transparency matter? Examining Brazil’s public procurement system JC Kohler, N Mitsakakis, F Saadat, D Byng, MG Martinez Globalization and health 11, 1-13, 2015 | 48 | 2015 |
| Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET D Byng, JI Lutter, ME Wacker, RA Jörres, X Liu, S Karrasch, H Schulz, ... International Journal of Chronic Obstructive Pulmonary Disease, 1423-1439, 2019 | 32 | 2019 |
| Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial VP Retèl, D Byng, SC Linn, K Jóźwiak, H Koffijberg, EJ Rutgers, ... European journal of cancer 137, 193-203, 2020 | 26 | 2020 |
| AI-based prevention of interval cancers in a national mammography screening program D Byng, B Strauch, L Gnas, C Leibig, O Stephan, S Bunk, G Hecht European Journal of Radiology 152, 110321, 2022 | 14 | 2022 |
| Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial JMNL Cardozo, D Byng, CA Drukker, MK Schmidt, MA Binuya, ... Annals of Oncology 33 (3), 310-320, 2022 | 13 | 2022 |
| Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence? D Byng, VP Retèl, M Schaapveld, J Wesseling, WH van Harten, ... Breast cancer research and treatment 187, 187-196, 2021 | 12 | 2021 |
| Preferences of treatment strategies among women with low-risk DCIS and oncologists D Byng, VP Retèl, EG Engelhardt, CGM Groothuis-Oudshoorn, JA van Til, ... Cancers 13 (16), 3962, 2021 | 10 | 2021 |
| Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study RSJM Schmitz, AW van den Belt-Dusebout, K Clements, Y Ren, C Cresta, ... bmj 383, 2023 | 8 | 2023 |
| Proofs for PLOS ONE paper: does pharmaceutical pricing transparency matter? Examining Brazil’s public procurement system JC Kohler, N Mitsakakis, F Saadat, D Byng, MG Martinez Globalization and Health 11, 2015 | 8 | 2015 |
| Surveillance imaging after primary diagnosis of ductal carcinoma in situ D Byng, SM Thomas, CN Rushing, T Lynch, A McCarthy, AB Francescatti, ... Radiology 307 (1), e221210, 2023 | 5 | 2023 |
| Abstract OT3-18-03: The PRAIM study: A prospective multicenter observational study of an integrated Artificial Intelligence system with live monitoring D Byng, N Eisemann, D Schüler, S Bunk, C Leibig, M Brehmer, S Elsner, ... Cancer Research 83 (5_Supplement), OT3-18-03-OT3-18-03, 2023 | 2 | 2023 |
| Homelessness and Access to Health Care: Policy Options and Considerations D Byng Healthy Dialogue 1 (1), 2012 | 2 | 2012 |
| Women diagnosed with ductal carcinoma in situ (DCIS) and healthcare providers’ views on active surveillance for DCIS. Results from focus groups and in-depth interviews E Engelhardt, D Byng, K Klaver, M Gerritsma, E Verschuur, ... European Journal of Cancer 138, S36, 2020 | 1 | 2020 |
| An early cost-effectiveness analysis of active surveillance for low-risk ductal carcinoma in situ D Byng, M Schaapveld, E Lips, F van Duijnhoven, J Wesseling, ... European Journal of Cancer 200, 2024 | | 2024 |
| ‘One size does not fit all’: Translational health technology assessment in early breast cancer and DCIS DT Byng | | 2022 |
| Subsequent invasive breast cancer risk after DCIS treatment in multinational PRECISION consortium cohorts comprising 48,576 patients RS Schmitz, AW van den Belt-Dusebout, K Clements, Y Ren, C Cresta, ... Cancer Research 82 (12_Supplement), 686-686, 2022 | | 2022 |
| Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortium RSJM Schmitz, SW van den Belt-Dusebout, C Cresta, YH Liu, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P1-22-02: Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortium RSJM Schmitz, SW van den Belt-Dusebout, C Cresta, YH Liu, ... Cancer Research 82 (4_Supplement), P1-22-02-P1-22-02, 2022 | | 2022 |
| An early economic evaluation of active surveillance for low-risk DCIS D Byng, M Schaapveld, EH Lips, FH van Duijnhoven, J Wesseling ‘ONE SIZE DOES NOT FIT ALL’, 109, 2022 | | 2022 |
